Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions

Autor: P. Astoul, P. Farisse, C. Boutin, Maud Brandely, J. R. Viallat, F. Rey
Rok vydání: 1993
Předmět:
Zdroj: Cancer. 71:4067-4071
ISSN: 1097-0142
0008-543X
DOI: 10.1002/1097-0142(19930615)71:12<4067::aid-cncr2820711243>3.0.co;2-d
Popis: Background. The authors assessed the tolerance and efficacy of intrapleural interleukin-2 (IL-2) in patients with malignant effusion. Methods. Twenty-three patients had a total of 25 metastatic pleural effusions; the patients were treated with recombinant IL-2 by means of a continuous intrapleural infusion for 5 days. The daily dosage used in this Phase I/II trial initially was 3 × 106 IU/m2/day; the dosage was increased with every third patient, culminating in a dosage of 24 × 106 IU/m2/day. Results. One patient who had received the highest dosage died of renal failure on day 8. Ninety-six percent of patients had Grade 2–3 fever, which was easily controlled with paracetamol administration. Two (8%) patients had pleural empyema. All other side effects were mild and resolved spontaneously by the end of treatment. The objective response rate was 21.7%. The five patients who responded to IL-2 therapy were alive 7–24 months after treatment, and the survival rate of the whole group was 59% after 13 months. Conclusion. A daily dose of 10–24 × 106 IU/m2/day of IL-2 administered intrapleurally gave response rates similar to those reported in the literature using the intravenous route, but a much lower morbidity rate was recorded.
Databáze: OpenAIRE
Externí odkaz: